The Dipeptidyl Peptidase 1 pipeline drugs market research report outlays comprehensive information on the Dipeptidyl Peptidase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Dipeptidyl Peptidase 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Infectious Disease, Genito Urinary System, and Dermatology which include the indications Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD), Gram-Negative Bacterial Infections, Complicated Intra-Abdominal Infections, Acute Renal Failure (ARF) (Acute Kidney Injury), Urinary Tract Infections, and Hidradenitis Suppurativa. It also reviews key players involved in Dipeptidyl Peptidase 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Dipeptidyl Peptidase 1 pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 2, 2, 1, and 1 respectively.
Dipeptidyl Peptidase 1 overview
Dipeptidyl Peptidase 1 is also known as Cathepsin C which is a protein encoded by a gene CTSC. This gene encodes a member of the peptidase C1 family and lysosomal cysteine proteinase that appears to be a central coordinator for activation of many serine proteinases in cells of the immune system. Defects in the encoded protein have been shown to be a cause of Papillon-Lefevre syndrome, an autosomal recessive disorder characterized by palmoplantar keratosis and periodontitis.
For a complete picture of Dipeptidyl Peptidase 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
